Who are BP1.3656 low dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vasotec, Calcium Channel Blockers, ACE-Inhibitor, captopril, Losartan (drug), Perindopril plus Amlodipine, Perindopril + Indapamide, RASi plus carvedilol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bp1-3656-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BP1.3656 low dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BP1.3656 low dose (BP1.3656 low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

phase 2 ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

BP1.3656 low dose (BP1.3656 low dose) — Bioprojet. BP1.3656 low dose is a medication that lowers blood pressure by acting on the renin-angiotensin system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BP1.3656 low dose TARGET	BP1.3656 low dose	Bioprojet	phase 2	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
Calcium Channel Blockers, ACE-Inhibitor	Calcium Channel Blockers, ACE-Inhibitor	University of Aarhus	marketed	Combination antihypertensive (calcium channel blocker + ACE inhibitor)	L-type calcium channels; Angiotensin-converting enzyme (ACE)
captopril, Losartan (drug)	captopril, Losartan (drug)	National Taiwan University Hospital	marketed	ACE inhibitor and angiotensin II receptor antagonist combination	ACE enzyme and AT1 receptor
Perindopril plus Amlodipine	Perindopril plus Amlodipine	University of Abuja	marketed	ACE inhibitor + Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels
Perindopril + Indapamide	Perindopril + Indapamide	Centre for Chronic Disease Control, India	marketed	ACE inhibitor + thiazide-like diuretic combination	Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
Bioprojet · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
Children's Hospital of Fudan University · 1 drug in this class
Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Ethicare GmbH · 1 drug in this class
Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BP1.3656 low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/bp1-3656-low-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing